Skip to main content
. Author manuscript; available in PMC: 2024 Jul 15.
Published in final edited form as: J Am Chem Soc. 2023 Jun 16;145(25):14155–14163. doi: 10.1021/jacs.3c05159

Figure 2: The degradation ability of TCO-ARV-771 with c(RGDyK)-Tz in HeLa cells.

Figure 2:

A) Immunoblot analysis of BRD4 levels from HeLa cells treated with TCO-ARV-771 for 16 h. B) Immunoblot analysis of BRD4 levels from HeLa cells treated with 0.4 μM TCO-ARV-771 and various concentration of c(RGDyK)-Tz. HeLa cells were treated with different concentrations of c(RGDyK)-Tz for 3 h followed by treatment with TCO-ARV-771 (0.4 μM) for 16 h. C) Immunoblot analysis of BRD4 levels from HeLa cells treated with positive control ARV-771. D) Immunoblot analysis of BRD4 levels from HeLa cells treated with various concentrations of TCO-ARV-771 and 1.0 μM c(RGDyK)-Tz. HeLa cells were treated with 1.0 μM c(RGDyK)-Tz for 3 h followed by treatment with different concentrations of TCO-ARV-771 for 16 h. E) Cell viability of HeLa cells with ARV-771, TCO-ARV-771, c(RGDyK)-Tz or TCO-ARV-771 and c(RGDyK)-Tz (2.5 equivalent, 3 h pretreatment) for 72 h.